![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hvivo Plc | LSE:HVO | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.35 | 1.28% | 27.60 | 27.20 | 28.00 | 27.60 | 27.25 | 27.25 | 660,775 | 10:22:59 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 56.04M | 16.12M | 0.0237 | 11.65 | 185.4M |
TIDMORPH
Open Orphan PLC
10 February 2020
10 February 2020
RNS REACH
Open Orphan Plc
("Open Orphan" or the "Company")
Value the Markets Webinar
Tuesday, 11 February 2020 at 7 pm
Open Orphan, the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce that the Company will be hosting a webinar for investors at 7pm on Tuesday 11(th) February. For those wishing to join the event the participant details are below.
Join via Website: https://vtm.clickmeeting.com/orph
Join via Phone: +44 (20) 7048-4146
When prompted please provide the Participant's PIN code 159543# followed by the # key
For further information please contact
+353 (0)1 644 Open Orphan plc 0007 Cathal Friel, Executive Chairman +44 (0)20 7347 Trevor Phillips, Chief Executive Officer 5350 Arden Partners plc (Nominated Adviser and Joint Broker) +44 (0)20 7614 John Llewellyn-Lloyd / Benjamin Cryer 5900 Davy (Euronext Growth Adviser and Joint Broker) +353 (0)1 679 Anthony Farrell 6363 Camarco (Financial PR) +44 (0)20 3757 Tom Huddart / Daniel Sherwen 4980
About RNS Reach announcements
This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.
Notes to Editors:
Open Orphan is a rapidly growing European full pharmaceutical services company with a focus on orphan drug and specialist services, comprising two commercial specialist CRO services businesses (Venn and hVIVO) and a developing early stage orphan drug genomics data platform business capturing valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools. In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and in January 2020 it completed the Merger with hVIVO plc. Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing and controls) , preclinical, phase I & II clinical trials design and execution. hVIVO, is a world leader in the provision of viral challenge studies, vaccine and viral laboratory services, supporting product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of the Coronavirus in 2020. The Merger with hVIVO created a European full pharma services company broadening the Company's customer base and with complementary specialist CRO services, widened the range of the Company's service offerings.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NRATMMBTMTBBBIM
(END) Dow Jones Newswires
February 10, 2020 06:17 ET (11:17 GMT)
1 Year Hvivo Chart |
1 Month Hvivo Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions